Published in Stroke Vasc Neurol on October 25, 2016
Tissue plasminogen activator for acute ischemic stroke. The National Institute of Neurological Disorders and Stroke rt-PA Stroke Study Group. N Engl J Med (1995) 47.15
Endovascular therapy after intravenous t-PA versus t-PA alone for stroke. N Engl J Med (2013) 14.78
Major causes of death among men and women in China. N Engl J Med (2005) 11.80
Combined intravenous and intra-arterial recanalization for acute ischemic stroke: the Interventional Management of Stroke Study. Stroke (2004) 4.67
The Interventional Management of Stroke (IMS) II Study. Stroke (2007) 3.83
Endovascular thrombectomy after large-vessel ischaemic stroke: a meta-analysis of individual patient data from five randomised trials. Lancet (2016) 3.43
Combined intravenous and intra-arterial r-TPA versus intra-arterial therapy of acute ischemic stroke: Emergency Management of Stroke (EMS) Bridging Trial. Stroke (1999) 2.85
Cause-specific mortality for 240 causes in China during 1990-2013: a systematic subnational analysis for the Global Burden of Disease Study 2013. Lancet (2015) 2.71
Standard-dose intravenous tissue-type plasminogen activator for stroke is better than low doses. Stroke (2014) 2.19
Alteplase at 0.6 mg/kg for acute ischemic stroke within 3 hours of onset: Japan Alteplase Clinical Trial (J-ACT). Stroke (2006) 1.99
Urgent therapy for stroke. Part I. Pilot study of tissue plasminogen activator administered within 90 minutes. Stroke (1992) 1.89
Low-Dose versus Standard-Dose Intravenous Alteplase in Acute Ischemic Stroke. N Engl J Med (2016) 1.83
Outcomes of thrombolytic therapy for acute ischemic stroke in Chinese patients: the Taiwan Thrombolytic Therapy for Acute Ischemic Stroke (TTT-AIS) study. Stroke (2010) 1.79
The combined approach to lysis utilizing eptifibatide and rt-PA in acute ischemic stroke: the CLEAR stroke trial. Stroke (2008) 1.79
Effects of 0.6 mg/kg intravenous alteplase on vascular and clinical outcomes in middle cerebral artery occlusion: Japan Alteplase Clinical Trial II (J-ACT II). Stroke (2010) 1.72
Urgent therapy for stroke. Part II. Pilot study of tissue plasminogen activator administered 91-180 minutes from onset. Stroke (1992) 1.64
Optimal dose for stroke thrombolysis in Asians: low dose may have similar safety and efficacy as standard dose. J Thromb Haemost (2012) 1.46
Developing clinical guidelines. West J Med (1999) 1.27
Combined IV and intra-arterial thrombolysis for acute ischemic stroke. Neurology (2005) 1.27
Combined intravenous and intra-arterial recombinant tissue plasminogen activator in acute ischemic stroke. Stroke (2000) 1.22
Factors related to intracranial hematoma formation in patients receiving tissue-type plasminogen activator for acute ischemic stroke. Stroke (1994) 1.09
Combined approach to lysis utilizing eptifibatide and recombinant tissue plasminogen activator in acute ischemic stroke-enhanced regimen stroke trial. Stroke (2013) 1.08
Analysis of coagulation and fibrinolysis during intravenous infusion of recombinant human tissue-type plasminogen activator in patients with acute myocardial infarction. Circulation (1986) 0.93
Low-Versus Standard-Dose Alteplase for Ischemic Strokes Within 4.5 Hours: A Comparative Effectiveness and Safety Study. Stroke (2015) 0.90
Thrombolysis with 0.6 mg/kg intravenous alteplase for acute ischemic stroke in routine clinical practice: the Japan post-Marketing Alteplase Registration Study (J-MARS). Stroke (2010) 0.89
Patients with thrombolysed stroke in Vietnam have an excellent outcome: results from the Vietnam Thrombolysis Registry. Eur J Neurol (2010) 0.88
Comparison of combined venous and arterial thrombolysis with primary arterial therapy using recombinant tissue plasminogen activator in acute ischemic stroke. J Stroke Cerebrovasc Dis (2008) 0.87
THrombolysis for Acute Wake-up and unclear-onset Strokes with alteplase at 0·6 mg/kg (THAWS) Trial. Int J Stroke (2014) 0.84
Simultaneous treatment with intravenous recombinant tissue plasminogen activator and endovascular therapy for acute ischemic stroke within 3 hours of onset. AJNR Am J Neuroradiol (2008) 0.82
Racial and genetic determinants of plasma factor XIII activity. Genet Epidemiol (2000) 0.81
Feasibility and safety of intravenous thrombolysis in multiethnic Asian stroke patients in Singapore. J Stroke Cerebrovasc Dis (2010) 0.81
Statistical analysis plan for evaluating low- vs. standard-dose alteplase in the ENhanced Control of Hypertension and Thrombolysis strokE stuDy (ENCHANTED). Int J Stroke (2015) 0.80
Complete Blalock-Taussig shunt obstruction in < 24 hours post-operative period in a neonate treated emergently using transcatheter angioplasty and low dose local recombinant TPA. Catheter Cardiovasc Interv (2013) 0.79
Comparison of partial (.6 mg/kg) versus full-dose (.9 mg/kg) intravenous recombinant tissue plasminogen activator followed by endovascular treatment for acute ischemic stroke: a meta-analysis. J Neuroimaging (2011) 0.78
Genetic association between FXIII and β-fibrinogen genes and women with recurrent spontaneous abortion: a meta- analysis. J Assist Reprod Genet (2015) 0.75
Finding the Right t-PA Dose for Asians with Acute Ischemic Stroke. N Engl J Med (2016) 0.75